TY - JOUR
T1 - Progressive supranuclear palsy’s economical burden
T2 - the use and costs of healthcare resources in a large health provider in Israel
AU - Barer, Yael
AU - Cohen, Raanan
AU - Grabarnik-John, Meital
AU - Ye, Xiaolan
AU - Zamudio, Jorge
AU - Gurevich, Tanya
AU - Chodick, Gabriel
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023/8
Y1 - 2023/8
N2 - Background: Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder with no disease modifying therapy currently available. Data on the costs associated with PSP are scarce. This study aims to assess the direct medical expenditure of patients with PSP (PwPSP) throughout disease course. Methods: This retrospective cohort study is based on the data of a large state-mandated health provider in Israel. We identified PwPSP who were initially diagnosed between 2000 and 2017. Each PwPSP was randomly matched to three health-plan members without PSP by birth-year, sex, and socioeconomic status. Healthcare resources’ utilization and related costs were assessed. Results: We identified 88 eligible PwPSP and 264 people in the reference group; mean age at diagnosis was 72.6 years (SD = 8.4) and 53.4% were female. The annual direct costs of PwPSP have risen over time, reaching US$ 21,637 in the fifth year and US$ 36,693 in the tenth year of follow-up vs US$ 8910 in the year prior diagnosis. Compared to people without PSP, PwPSP had substantially higher medical expenditure during the years prior- and post-index date. Conclusion: The present study demonstrates higher economic burden, which increases with time, in PwPSP as compared to those without.
AB - Background: Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder with no disease modifying therapy currently available. Data on the costs associated with PSP are scarce. This study aims to assess the direct medical expenditure of patients with PSP (PwPSP) throughout disease course. Methods: This retrospective cohort study is based on the data of a large state-mandated health provider in Israel. We identified PwPSP who were initially diagnosed between 2000 and 2017. Each PwPSP was randomly matched to three health-plan members without PSP by birth-year, sex, and socioeconomic status. Healthcare resources’ utilization and related costs were assessed. Results: We identified 88 eligible PwPSP and 264 people in the reference group; mean age at diagnosis was 72.6 years (SD = 8.4) and 53.4% were female. The annual direct costs of PwPSP have risen over time, reaching US$ 21,637 in the fifth year and US$ 36,693 in the tenth year of follow-up vs US$ 8910 in the year prior diagnosis. Compared to people without PSP, PwPSP had substantially higher medical expenditure during the years prior- and post-index date. Conclusion: The present study demonstrates higher economic burden, which increases with time, in PwPSP as compared to those without.
KW - Direct costs
KW - Economic burden
KW - Healthcare services
KW - Medical expenditure
KW - Progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85153048696&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00415-023-11714-1
DO - https://doi.org/10.1007/s00415-023-11714-1
M3 - مقالة
C2 - 37069439
SN - 0340-5354
VL - 270
SP - 3770
EP - 3778
JO - Journal of Neurology
JF - Journal of Neurology
IS - 8
ER -